For research use only. Not for therapeutic Use.
Lanifibranor(CAT: I007614) is a pharmaceutical compound also referred to as IVA-337. Functioning as a peroxisome proliferator-activated receptor (PPAR) agonist, Lanifibranor modulates the activity of these nuclear receptors involved in various biological processes, including metabolism and inflammation. By activating PPARs, Lanifibranor may contribute to the regulation of gene expression and metabolic pathways, potentially offering therapeutic benefits in conditions such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and other disorders with underlying inflammation and metabolic disturbances.
| Catalog Number | I007614 |
| CAS Number | 927961-18-0 |
| Synonyms | Lanifibranor; IVA-337; IVA 337; IVA337.;4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid |
| Molecular Formula | C19H15ClN2O4S2 |
| Purity | ≥95% |
| Target | PARP agonist |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| SMILES | O=C(O)CCCC(N1S(=O)(C2=CC=C3N=CSC3=C2)=O)=CC4=C1C=CC(Cl)=C4 |
| Reference | </br>1:Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2016 Dec 12:1-14. [Epub ahead of print] PubMed PMID: 27899043. |
